U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675824) titled 'REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension' on June 23.
Brief Summary: This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP).
REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure.
The study is looking at:
* What ...